CJC-1295 + Ipamorelin (blend) vs Ipamorelin

Ipamorelin alone acts only at the ghrelin receptor (GHS-R1a). The blend adds CJC-1295 without DAC, which acts at the pituitary GHRH receptor — the other input that shapes a GH pulse. No published study has evaluated the blend itself.

HPLC tested · JanoshikJanoshik CertificatesNationwide DeliveryResearch Only

CJC-1295 + Ipamorelin (blend)

This is a blend rather than a single compound, and no published study has evaluated this specific two-peptide combination — the evidence below is the literature for each constituent, cited separately.

BEST STUDIED FOR

Combined GHRH- and ghrelin-receptor GH-pulse research

R609View product →

Ipamorelin

Ipamorelin is a synthetic pentapeptide that selectively binds the growth-hormone-secretagogue receptor (the ghrelin receptor).

BEST STUDIED FOR

Selective GH-pulse research

R489View product →

Side by side · to buy

Price, purity and dispatch

Compare	CJC-1295 + Ipamorelin (blend)10mg	Ipamorelin10mg
Price	R609	R489
Cost per mg	R60.9 / mgBlend total	R48.9 / mg
Purity (Janoshik)	On request	99.763%HPLC, published
Stock	Restocking	Restocking
Dispatch	When restocked	When restocked
Certificate	Request CoA	View CoA →
Literature	3 papers →	3 papers →
Research focus	Combined GHRH- and ghrelin-receptor GH-pulse research	Selective GH-pulse research
	Notify me	Notify me

Prices are read live from the catalogue. Cost per mg is the vial price over its stated mg. Purity is shown only where the certificate is published. Every compound is supplied for laboratory research only.

RESEARCH PROFILES

0–10 per area, scored from the depth of published research — not a measure of effect.

Area	CJC-1295 + Ipamorelin (blend)	Ipamorelin
Fat Loss & Metabolism	5	5
Appetite Control	3	3
Muscle & Body Composition	9	8
Recovery & Repair	7	7
Skin, Hair & Glow	5	5
Gut & Immune	5	5
Cognition & Focus	4	4
Mood & Calm	4	4
Sleep & Recovery Rhythm	7	7
Longevity & Energy	6	6

SIDE BY SIDE

	CJC-1295 + Ipamorelin (blend)	Ipamorelin
The key difference	GHRH analogue + ghrelin agonist, one vial	Ghrelin agonist alone
Class	GH secretagogues	GH secretagogues
Mechanism	This is a blend rather than a single compound, and no published study has evaluated this specific two-peptide combination — the evidence below is the literature for each constituent, cited separately.	Ipamorelin is a synthetic pentapeptide that selectively binds the growth-hormone-secretagogue receptor (the ghrelin receptor).
Status	A research blend of two investigational GH secretagogues; neither component is an approved medicine and the blend itself has not been studied.	Investigational ghrelin-receptor agonist; reached clinical trials for post-operative ileus but was not approved.
Reported safety signals	No human safety data for the blend; each component has only limited, short-term human exposure.	Clinical-trial exposure is limited to short courses; no long-term human safety data.
A key study	Measured GH responses to GHRH(1-29)-NH2 and a D-Ala2-substituted analogue in normal men across a dose range. (Peptides 1985, PMID 2866496)	The characterisation study describing ipamorelin as the first GH secretagogue to release growth hormone with a selectivity comparable to GHRH in animals. (Eur J Endocrinol 1998, PMID 9849822)

WHEN TO RESEARCH WHICH

Ipamorelin alone isolates the ghrelin-receptor arm; the blend lets both GH-pulse inputs be studied from one vial. Both are discussed here strictly as research compounds; nothing on this page is medical advice or a dosing guide.

REFERENCES (PUBMED)

[CJC-1295 + Ipamorelin (blend)] Growth hormone responses to growth hormone-releasing hormone (1-29)-NH2 and a D-Ala2 analog in normal men — Peptides 1985. PMID 2866496
[CJC-1295 + Ipamorelin (blend)] Human growth hormone-releasing hormone hGHRH(1-29)-NH2: systematic structure-activity relationship studies — J Med Chem 1998. PMID 9513600
[CJC-1295 + Ipamorelin (blend)] Ipamorelin, the first selective growth hormone secretagogue — Eur J Endocrinol 1998. PMID 9849822
[Ipamorelin] Ipamorelin, the first selective growth hormone secretagogue — Eur J Endocrinol 1998. PMID 9849822
[Ipamorelin] The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation — Growth Horm IGF Res 2001. PMID 11735244
[Ipamorelin] Growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss — Physiol Behav 2024. PMID 39043357

FREQUENTLY ASKED

What is the difference between CJC-1295 + Ipamorelin (blend) and Ipamorelin?

What is the regulatory status of CJC-1295 + Ipamorelin (blend) and Ipamorelin?

CJC-1295 + Ipamorelin (blend): A research blend of two investigational GH secretagogues; neither component is an approved medicine and the blend itself has not been studied. Ipamorelin: Investigational ghrelin-receptor agonist; reached clinical trials for post-operative ileus but was not approved.

What safety signals have been reported?

CJC-1295 + Ipamorelin (blend): No human safety data for the blend; each component has only limited, short-term human exposure. Ipamorelin: Clinical-trial exposure is limited to short courses; no long-term human safety data.

Which studies is this comparison based on?

For CJC-1295 + Ipamorelin (blend): “Growth hormone responses to growth hormone-releasing hormone (1-29)-NH2 and a D-Ala2 analog in normal men” (PMID 2866496); “Human growth hormone-releasing hormone hGHRH(1-29)-NH2: systematic structure-activity relationship studies” (PMID 9513600); “Ipamorelin, the first selective growth hormone secretagogue” (PMID 9849822). For Ipamorelin: “Ipamorelin, the first selective growth hormone secretagogue” (PMID 9849822); “The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation” (PMID 11735244); “Growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss” (PMID 39043357).